Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141627 | 0.91 | USP30 (0.43) | EGFRBTKUSP30PIK3CAFGFR4 | |
| SCHEMBL12405526 | 0.83 | EGFR (0.43) | EGFRBTKUSP30PIK3CACSNK2A1 | |
| SCHEMBL30412730 | 0.83 | EGFR (0.43) | EGFRBTKUSP30PIK3CACSNK2A1 | |
| SCHEMBL12405532 | 0.83 | EGFR (0.43) | EGFRBTKUSP30PIK3CACSNK2A1 | |
| SCHEMBL2936534 | 0.81 | EGFR (0.42) | EGFRBTKUSP30PIK3CACSNK2A1 | |
| SCHEMBL2878054 | 0.80 | EGFR (0.45) | EGFRBTKUSP30KDM1ANOTUM | |
| SCHEMBL30418523 | 0.80 | EGFR (0.45) | EGFRBTKUSP30KDM1ANOTUM | |
| SCHEMBL2937583 | 0.78 | EGFR (0.41) | EGFRBTKUSP30PIK3CACSNK2A1 | |
| SCHEMBL28950688 | 0.77 | USP30 (0.45) | EGFRBTKUSP30PIK3CACSNK2A1 | |
| SCHEMBL21597010 | 0.77 | GRM5 (0.47) | EGFRBTKUSP30PIK3CAFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| EP-2001887-B1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | disclosed |
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-7709483-B2 | Pyrrolo-quinoxalinone derivatives as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-1954697-B1 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-02-24 | — | — | EP | disclosed |
| EP-2136807-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20080280892-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| WO-2008125594-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| EP-1954697-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007081597-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | EGFR 944/4885BTK 2520/4885USP30 4422/4885 |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | NQO2, PPOX, ASNS | EGFR 3998/4885BTK 3100/4885USP30 3065/4885 |
| US-20080221110-A1 | Compounds | NRDC, NISCH, MRPL21 | EGFR 891/4885BTK 3403/4885USP30 3885/4885 |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | EGFR 4751/4885BTK 3986/4885USP30 4377/4885 |
| US-20080280892-A1 | Compounds | NRDC, NACA, NAA50 | EGFR 1531/4885BTK 3878/4885USP30 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.